Miraculins, a Canada-based medical diagnostic company, has acquired VeraLight's SCOUT DS technology, which screens diabetes by non-invasively measuring changes in the skin composition.
These changes in the skin composition indicates whether the patient is suffering with pre-diabetes or type 2 diabetes.
Miraculins president and CEO Christopher Moreau said with diabetes being the fastest growing disease in history, as well as a major risk factor for coronary artery disease, the SCOUT DS along with the PreVu POC Test will represent an assembly of new, non-invasive tools to assist in the assessment of at-risk individuals worldover.
"This acquisition will provide Miraculins and our distribution network – including the retail pharmacy segment – with another significant competitive edge, while allowing us to move Miraculins closer to its corporate mission of becoming a global leader in the provision of diagnostic tests and risk assessment technologies, including non-invasive screening platforms," Moreau added.
The SCOUT DS will join Miraculins’ PreVu Skin Cholesterol Point-of-Care (POC) Test, another non-invasive screening technology.
Indicated to be used for the non-invasive screening of individuals over 18 years who are at risk of getting pre-diabetes and/or type 2 diabetes, the SCOUT DS technology can test individuals in 80 seconds without drawing blood.
The SCOUT DS will be sold individually and along with PreVu POC Test.
The technology has received clearance from Health Canada for distribution. Recently, it has secured CE Mark in the EU and regulatory approval to sell the device in Mexico.